Clinical trial · Interventional
Personalized Treatment of Urogenital Cancers Depends on the Microbiome
NCT03962920CI-TRIAL-00073377recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomized controlled trial where patients undergoing surgical treatment for urogenital cancers will be randomized in a two arms study: surgical treatment + antibiotics OR surgical treatment + placebo.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Microbial Disease | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Other | — | UNRESOLVED |
| Tigecycline 50 MG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Surgical treatment + antibiotics
- description
- Use antibiotic
- interventionNames
- Drug: Tigecycline 50 MG
- type
- PLACEBO_COMPARATOR
- label
- surgical treatment + placebo
- description
- Use placebo
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- recurrence rate after surgical treatment of tumour
- timeFrame
- 5 years after treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy verified diagnosis of urological cancer, localized disease Exclusion Criteria: * Hospitalization within three months of surgery * Antibiotics within three months of surgery * Infectious disease, including UTI's within three months of surgery * History of cancers of the genitourinary tract * Diabetes
References
Publications (0)
Data not yet available
No reference posted for this study.